enow.com Web Search

  1. Ads

    related to: orange book patents

Search results

  1. 4ORA.TI -

    Yahoo Finance

    10.39-0.30 (-2.85%)

    at Mon, Apr 15, 2024, 10:37AM EDT - U.S. markets close in 3 hours 28 minutes

    Delayed Quote

    • Open 10.39
    • High 10.39
    • Low 10.39
    • Prev. Close 10.69
    • 52 Wk. High 10.39
    • 52 Wk. Low 10.39
    • P/E N/A
    • Mkt. Cap N/A
  2. Results from the WOW.Com Content Network
  3. Approved Drug Products with Therapeutic Equivalence ...

    en.wikipedia.org/wiki/Approved_Drug_Products...

    Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book, is a publication produced by the United States Food and Drug Administration (FDA), as required by the Drug Price and Competition Act (Hatch-Waxman Act). The Hatch-Waxman Act was created to '"strike a balance between two competing policy interests ...

  4. Orange-Book-Standard - Wikipedia

    en.wikipedia.org/wiki/Orange-Book-Standard

    Orange-Book-Standard. Orange-Book-Standard (Az. KZR 39/06) is a decision issued on May 6, 2009 by the Federal Court of Justice of Germany ( German: Bundesgerichtshof, BGH) on the interaction between patent law and technical standards, and more generally between intellectual property law and competition law.

  5. US FTC disputes over 100 medical patents listed with FDA ...

    www.aol.com/news/us-ftc-disputes-listing-more...

    "Wrongfully listed Orange Book patents by pharma companies can raise drug prices for Americans, harm fair competition, and delay better drugs," FTC Chair Lina Khan said on X, formerly known as ...

  6. Drug Price Competition and Patent Term Restoration Act

    en.wikipedia.org/wiki/Drug_Price_Competition_and...

    t. e. The Drug Price Competition and Patent Term Restoration Act (Public Law 98-417), informally known as the Hatch-Waxman Act, is a 1984 United States federal law that established the modern system of generic drug regulation in the United States. The Act's two main goals are to facilitate entry of generic drugs into the market and to ...

  7. Reasonable and non-discriminatory licensing - Wikipedia

    en.wikipedia.org/wiki/Reasonable_and_non...

    Reasonable and non-discriminatory ( RAND) terms, also known as fair, reasonable, and non-discriminatory ( FRAND) terms, denote a voluntary licensing commitment that standards organizations often request from the owner of an intellectual property right (usually a patent) that is, or may become, essential to practice a technical standard. [1]

  8. How Drug Makers Manipulate Patents to Keep Insulin ... - AOL

    www.aol.com/lifestyle/drug-makers-manipulate...

    For premium support please call: 800-290-4726 more ways to reach us

  9. Essential patent - Wikipedia

    en.wikipedia.org/wiki/Essential_patent

    Patent infringement, the commission of a prohibited act with respect to a patented invention; Patent thicket, a negatively connotated term for an overlapping set of patent rights; Orange-Book-Standard, a German decision on the interaction between patent law and technical standards; Standardization, the process of creating technical standards

  10. Chemical patent - Wikipedia

    en.wikipedia.org/wiki/Chemical_patent

    A 2021 analysis of the most valuable US pharmaceutical patents published in the Orange Book between 2000 and 2018 showed that ca. 25% of these patents end up litigated in courts, but only 26% of these litigated patents are invalidated, well below the overall patent invalidation rate of 43%. 94% of these invalidated patents are not the highly ...

  11. Fingolimod - Wikipedia

    en.wikipedia.org/wiki/Fingolimod

    Fingolimod, sold under the brand name Gilenya, is an immunomodulating medication, used for the treatment of multiple sclerosis. [3] Fingolimod is a sphingosine-1-phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from contributing to an autoimmune reaction. It has been reported to reduce the rate of ...

  12. Novartis v. Union of India & Others - Wikipedia

    en.wikipedia.org/wiki/Novartis_v._Union_of_India...

    Mr. Justice Aftab Alam [1] Novartis v. Union of India & Others is a landmark decision by a two-judge bench of the Indian Supreme Court on the issue of whether Novartis could patent Gleevec in India, and was the culmination of a seven-year-long litigation fought by Novartis. The Supreme Court upheld the Indian patent office's rejection of the ...